

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**September 15, 2020**

---

---

**I Continuing Review**

**10126**, A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma (Protocol Version Date 02/14/19)

---

---

**II Continuing Review**

**10170**, A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies (Protocol Version Date 06/05/20)

---

---

**III Continuing Review**

**10184**, Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (Protocol Version Date 03/16/20)

---

---

**IV Continuing Review**

**10276**, A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (Protocol Version Date 06/29/20)

---

---

**V Continuing Review**

**10324**, A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With M3814 in Platinum-Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) (Protocol Version Date 07/16/20)

---

**VI New Study - Initial Review**

**10384**, A Phase 1b/2 Study of Hu5F9-G4 (magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T- cell Lymphoma (Protocol Version Date 08/07/20)

---

**VII New Study - Initial Review**

**10406**, Phase 1/1b Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers (Protocol Version Date 08/06/20)

---